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Summary. With regard to oral contraceptives, much research
has concentrated on venous thrombosis and on the coronary and
cerebral forms of atherosclerotic disease, while peripheral
arterial disease (PAD) has received little attention. In this
case-control study, we assessed oral contraceptive use and
the risk of PAD in young women using a population-based
case-control study. The women were 18-49years of age, and
had been admitted to a collaborating hospital between January
1990 and October 1995, and had a diagnosis of PAD. Partici-
pants were patients with PAD (n = 152), and control women
(n = 925), identified by random digit dialing. The diagnosis of
PAD was based almost exclusively on intra-arterial angiogra-
phy. Patients and control subjects filled out the same structured
questionnaire, which included questions on medical history,
cardiovascular risk factors, and contraceptive use. The adjusted
odds ratio for PAD in women using any type of oral contra-
ceptives vs. no use, was 3.8 (95% CI 2.4-5.8). When first
generation oral contraceptive use was compared with no use, the
odds ratio was 8.7 (95% CI 3.6-21.3). For second and third
generation oral contraceptives, the adjusted odds ratios (com-
pared with non-users) were 2.6 (95% CI 1.4-4.9) and 3.0 (95%
CI 1.4-6.6), respectively. This is the first study on oral contra-
ceptive use and PAD in humans. All lypes of oral contraceptives
were associated with an increased risk of PAD.
Keywords: epidemiology, oral contraceptives, peripheral arter-
ial disease, risk factors.
The effects of combination oral contraceptives on cardiovas-
cular health of women have been a subject of epidemiological
research for more than 35 years [l,2]. These studies pointed to a
link between oral contraceptive use and vascular complications,
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both venous and arterial. The recognition of these adverse
vascular events associated with the use of oral contraceptives
resulted in several modifications of the dose of estrogen and
type of progestagen in combination preparations [3-6].
In 1995, several articles reported that users of third genera-
tion oral contraceptives containing gestodene or desogestrel had
a twofold higher risk of venous thromboembolic disease than
non-users [7-10]. It has been suggested that third generation
oral contraceptives would be protective against arterial throm-
bosis by a favorable effect on the lipid profile: increasing high
density lipoprotein (HDL)-cholesterol and lowering low density
lipoprotein (LDL)-cholesterol [11,12]. Several studies have
been aimed at the coronary and cerebral forms of atherosclero-
tic disease, but none at peripheral arterial disease (PAD) and its
association with oral contraceptive use.
PAD is rare in young women. Co-morbidity in patients with
premature onset of PAD is high, and it carries a poor prognosis,
with a high incidence of vascular graft occlusion, amputation
and death [13,14].
We conducted a case-control study among young women in
the Netherlands to assess oral contraceptives äs a risk factor for




The RATIO study (Risk of Arterial Thrombosis In relation to
Oral Contraceptives) is a multicenter, population based case
control study. The study consists of three substudies for vascular
diseases (stroke, myocardial infarction, and PAD) in relation to
oral contraceptive use among women 18-49 years of age in the
Netherlands. The results for myocardial infarction and stroke
are reported separately. The study protocol was approved by the
ethics committees of the participating hospitals (see Appendix).
Identification of patients
Women were eligible patients if they were aged 18-49 years,
had been admitted to a collaborating hospital between January
1990 and October 1995, and had an angiographically confirmed
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diagnosis of PAD The end date was chosen because at that time
several studies presented results of mcreased nsk of venous
thromboembolic disease in women, who used desogestrel and
gestodene-containmg oral contraceptives [15] Consequently,
changes m prescnption of oral contraceptives may have
occurred which could have mfluenced the results All patients
were identified by means of the local Hospital Registration
Systems
PAD was diagnosed when patients presented typical Symp-
toms of mtermittent claudication (crampmg pain of the calves
or buttocks duting exercise), and had an ankle-arm Index m rest
less then 0 90 with a decrease of more than 20% after exercise
[16] Furthermore, all patients underwent intra-arterial angio-
graphy for evaluation of their chronic lower extremity ischemia
The arteriograms were reviewed and scored by two radiologists
Only patients with an atherosclerotic lesion and äs a conse-
quence a lummal diameter reduction of more than 50% were
included for analyses This implies that only patients with
atherosclerotic penpheral vessel disease were included and
patients with only acute thrombotic or embolic occlusion
(i e m the absence of atherosclerotic lesions locally), or patients
with angutis were excluded Also patients with a history of
cerebral disease, coronary heart disease, or venous thromboem-
bolic disease were excluded, because prescnption of oral con-
traceptives is discouraged m these patients
Of the 198 ehgible patients admitted dunng the study period,
20 women died between diagnosis of PAD and the start of the
study in 1996 Of the remammg 178 patients, 13 could not be
located despite extensive efforts Therefore, 165 questionnaires
were submitted from which 152 (92%) were returned
Control women
This project included three types of arterial disease, i e
ischemic stroke, myocardial infarction and PAD, which are
reported separately We proceeded to mclude one large control
group to which each of the three groups of patients was
contrasted The population-based group of control women
was identified by random digit dialing (RDD) [17] In this
method, random telephone numbers are dialed, and households
are ascertamed for ehgible (age, sex) individuals, who are
subsequently asked to participate Since age, area of residence
and calendar year were potential confounding factors, we
wished to be able to adjust for these variables äs efficiently
äs possible The control women were recruited m the same
geographic areas äs the women of the three patient groups
combmed (six areas of residence widely distnbuted over the
country) and control questionnaires were assigned an mdex year
corresponding to the event years of the three patient groups
combmed (1990-95) The control group may therefore be seen
äs a sample of the population that is stratified on age, area of
residence and calendar year, and therefore adjustment for these
factors is appropnate For the control women, six question-
naires with mdex years 1990-95 were available to compare the
questions concernmg oral contraceptive use, history of hyper-
tension, diabetes, hypercholesterolaemia and current smokmg
for each mdex year with the patients The mdex date of each
control woman was the first of July of the mdex year Each
control woman completed one questionnaire for one mdex date
A total number of 1259 ehgible women were reached by
random digit dialing Control women m the older age groups
were oversampled to mimmize the age difference between the
patients and the control women Because the upper age limit
was fixed on 49 years of age, oversamphng in the older age
group was achieved by mcreasmg the lower age limit from
18 years to 35 years of age, dunng the final months of control
recruitment Of these 1259 controls, 220 (17%) refused to
participate The reasons for refusal were no mterest (81%) or
lack of time (19%) So a questionnaire was sent to 1039 control
subjects who were ehgible and free of pnor cardiovascular
disease, 925 questionnaires were returned (73%) To achieve
optimal participation m the patient and control group we firstly
submitted the questionnaires, and when not returned one tele-
phone call was made to ask why the questionnaire was not
returned
Data collection
Patients and control women were asked to fill out the same
structured questionnaire comprismg questions on demographic
characteristics, medical history of cardiovascular nsk factors,
obstetric history, oral contraceptive use, medication, and a
family history of vascular disease Color photographs of all
oral contraceptive pills marketed m the Netherlands weie used
to help women recall specific brands of oral contraceptives
used Current oral contraceptive use was defined äs use withm
l month before the mdex date
Oral contraceptives were divided into four categones accord-
mg to the type of progestagens (i) first generation oral contra-
ceptives, contammg lynestrenol and norethisterone, (n) second
generation oral contraceptives, contammg levonorgestrel, (in)
third generation oral contraceptives, contammg desogestrel or
gestodene and (iv) oral contraceptives contammg other types of
progestagens
Smoking was defined äs havmg smoked m the year before the
mdex date Body mass mdex (BMI) was calculated äs body
weight (kg) divided by height squared (m2) Obesity was
defined äs a body mass mdex >27 3 kg m"2 Women were
classified äs hypertensive, diabetic or hypercholesterolaemic
when they reported a physician's diagnosis or were taking
medication for these conditions before the mdex date Family
history of cardiovascular disease was defined äs the presence of
myocardial infarction, stroke or PAD under 60 years of age in
first degree relatives
Statistical analysis
We calculated univanate odds ratlos äs estimates of the relative
nsk of PAD with the use of the vanous categones of oral
contraceptives Odds ratlos and 95% confidence mtervals (95%
CI) were calculated by unconditional logistic regression mod-
els, and adjusted for Ihe stratification factors age, area of
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residence and calendar year In addition, odds ratlos were
adjusted for putative confounding factors, i e smoking,
hypercholesterolaemia, diabetes, hypertension and alcohol
use, by multivanate models To allow a fair companson of
third vs second generation progestagens, we hmited analyses to
oral contraceptives contaimng 30 μg ethmylestradiol To eval-
uate the effect of estrogen dose without the mfluence of the
progestagen type we hmited analyses to oral contraceptives
contaimng levonorgestrel We also conducted subgroup ana-
lyses to assess the possibihty of interaction between use of oral
contraceptives and major cardiovascular nsk factors, such äs
smoking, diabetes, hypertension, hypercholesterolemia, and
obesity In the remamder of the text, all odds ratlos are adjusted
for the stratification factors age, area of residence and calendar
year, unless additional adjustment is mentioned
Results
Table l summarizes the characteristics and nsk factors of 152
patients with PAD and 925 control subjects The age of the
patients vaned between 25 and 49 years of age (mean 44 years)
Control women were 18-49 years of age (mean age 38 years)
Compared with control women, patients had a lower education
level and more often reported a history of hypertension, hyper-
cholesterolemia or diabetes A high percentage (92%) of
the patients was current smoker at the time of diagnosis
Patients more often reported a family history of cardiovascular
disease
Table 2 shows the use of different types of oral contracep
tives We found 78 patients (51%) and 348 control women
(38%) who were current users of oral contraceptives Thirty-
four (22%) patients used second generation oral contraceptives
and 14 (9%) used third generation oral contraceptives, com-
pared with 173 (19%) and 110 (12%), respectively, m the
control group Two control women used hormone replacement
therapy
Table l Baselme characteristics of young women with penpheral artenal
disease (PAD) and control women
Table 2 Oral contraceptive use m young women with penpheral artenal
disease (PAD) and control women
Age (mean SD)
Education
Pnmary school or less
Secondary school









Family history of cardiovascular disease
SD Standard deviation Data are number (
































































Data are numbers (%) unless otherwise indicated "Includmg oral
contraceptives contaimng cyproterone norgestimate and progestagen only
The nsk of PAD m women currently usmg any type of oral
contraceptives was almost fourfold increased compared with
non-users (OR = 3 8,95% CI2 4-5 8, adjusted for stratification
factors) Further adjustment for putative confounding factors
did not affect the estimate
Table 3 shows the adjusted odds ratios for PAD m relation to
oral contraceptive use stratified for age categories The nsk was
clearly elevated in all three age categories
Women who used first generation oral contraceptives had an
almost mnefold increased nsk of PAD compared with women
who did not use oral contraceptives, odds ratio 8 7 (95% CI 3 6-
21 3) (Table 4) Compared with non-users, the adjusted odds
ratio for PAD in women who used second generation oral
contraceptives contaimng 30 μg ethmylestradiol was 2 6
(95% CI l 4̂ 1 9) The odds ratio for third generation oral
contraceptives with the same amount of ethmylestradiol was
3 0 (95% CI l 4-6 6) The nsk of third generation oral contra-
ceptives contaimng 30 μg ethmylestradiol did not differ from
that of second generation oral contraceptives with the same
amount of estrogen (OR l l, 95% CI 0 5-2 5) The results did
not change when nsk estimates were additionally adjusted for
putative confounders
The use of oral contraceptives contammg higher doses of
estrogen (= 50 μg), was associated with an adjusted odds ratio
for PAD of 19 8 (95% CI 7 7-51 1) This was much higher than
the odds ratio of preparations with low dose estrogens (<50 μg),
Table 3 Odds ratios (95% CI) for penpheral artenal disease (PAD) in




















3 1 (1 8-5 3)
OC oral contraceptives Data are numbers (%) unless otherwise indicated
'Adjusted for stratification factors (area of residence and calendar year)
f Nine control women were left out of the analysis oral contraceptive use
was unknown m seven women and two women used hormone replacement
therapy
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Table4 Adjusted odds ratios CI) penpheral artenal disease (PAD) m lelation to different types of progestagens















3 8 (2 4-5 8)
8 7 (3 6-21 3)
2 6 (1 4-Λ 9)
3 0 (1 4-6 6)
OR (95% CI)f
4 0 (2 5-6 3)
9 3 (4 0-21 4)
24 (1 2-47)
3 3 (1 5-7 3)
OR relative to non users 74 patients and 568 control women 'Adjusted for stratification factors (age, area of residence, and calendar year) fAdjusted for
stratification factors, hypertension, diabetes melhtus, hypercholesterolemia smokmg, and alcohol use |Analyses are restncted to oral contraceptives
contammg 30 μg ethinylestradiol Excluded were 23 women who used oral contraceptives contammg 50 μg ethinylestradiol, 59 women who used second
generation triphasic oral contraceptives, 17 women who used 20 μg ethinylestradiol and three women who used third generation tnphasic oral
contraceptives Eleven control women were excluded because of missmg data of ethinylestradiol concentration
Table 5 Adjusted odds ratlos (95% CI) for penpheral artenal disease (PAD)
m relation to different doses of estrogens
Control
Patients subjects OR*
(n) (n) (95% CI)
Estrogen dose
50 μg ethinylestradiol vs no usef 2
30 μg ethinylestradiol vs no usef 17




3 1 (0 4-19 5)
1 6 (1 1-2 2)
0 6 (0 1-5 3)
'Adjusted for stratification factors (age, area of residence, and calendar
year fOR relative to non-users 74 patients and 568 control women
Analyses were restncted to oral contraceptives with 50 μg ethinylestradiol
and 30 μg ethinylestradiol and only with the progestagen levonorgestrel
adjusted odds ratio 2 4 (95% CI l 5-3 9) To evaluate the effect
of estrogen dose without the mfluence of the progestagen type
we limited the analysis to brands contammg the progestagen
levonorgestrel (Table 5) Users of oral contraceptives with 50 μg
ethinylestradiol (and 125μg levonorgestrel) had a 3 1-fold
mcreased nsk (95% CI 0 4-19 5) compared with non-users
Users of oral contraceptives with 30 μg ethinylestradiol (and
150μg levonorgestrel) had a l 6-fold mcreased risk (95% CI
l 1-2 2) compared with non-users In a direct companson of
preparations with 30 μg and 50 μg ethinylestradiol the adjusted
odds ratio was 0 6 (95% CI 0 1-5 3)
Table 6 shows odds ratios associated with oral contraceptive
use among patients and control subjects with and without any of
the classical cardiovascular risk factors Among non-users,
smokmg, hypertension, hypercholesterolemia and diabetes
clearly mcreased the risk When combmed with the use of oral
contraceptives, the relative nsks became very high among smo-
kers (OR = 36), hypercholesterolaemic women (OR = 50), and
diabetic women (OR = 40), mdicatmg synergistic effects
Discussion
Results of the study
Our study is the first to mvestigate oral contraceptives äs a nsk
factor for PAD We found that current users of oral contra-
ceptives were at threefold mcreased nsk for PAD m companson
with non-users When first, second and third generation puls
were compared with non-users and analyzed separately, we
found a highly elevated risk for first generation users, and an
almost threefold mcreased risk for second and third generation















19 1 (7 2-50 5)
1 (reference)








6 1 (1 5-25 0)
359 (135-959)































4 1 (2 6-6 5)
40 1 (7 5-213 9)
3 8 (2 3-6 3)
7 9 (3 6-17 6)
Odds ratios are relative to the reference category and are adjusted for stratification factors (age, area of residence, calendar year) Note totals may differ
due to missmg data
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users Third geneiation oral contraceptives use resulted m a
threefold mcreased nsk (95% CI l 4-6 6) The nsk of oral
contraceptives was even more elevated m combination with the
presence of risk factors for PAD, i e smokmg, hypertension,
hypercholesterolemia and dmbetes
Effect of other nsk factors
Univanate analysis confirmed the established role of smoking
äs a major nsk factor for penpheral vascular disease and of
other cardiovascular risk factors such äs hypertension, hyper-
cholesterolemia, and diabetes Only 12 of 152 women were
non-smokers This mdicates that smoking is a strong nsk factor
for PAD, and is m fact nearly a condition for its occurrence
PAD is a rare disease in young women So, even though oral
contraceptives increase nsk m non-smokers this will lead to low
probabilities of disease However, the combination of smoking
and oral contraceptive use revealed an odds ratio of 35 9 (95%
CI 13 5-95 9), which suggests a synergeüc effect of these two
factors Such an effect has previously been reported only for
myocardial infarction and stroke [18-24]
Compar/son of the results with earlier reports
Although there are no studies on oral contraceptive use and PAD
m young women, both chnical and animal-expenmental evi-
dence suggests that female steroids have a direct effect on the
artenal wall In 1964 Danforth demonstrated histological
changes in the wall of arteries after admimstration of ovulation
Inhibitors Remarkably, most marked changes were found in the
distal aorta [25] In 1970, Irey descnbed microscopic changes in
arteries in young women who used oral contraceptives [26] In
1977, Van Vroonhoven reported long-term use of oral contra-
ceptive agents in 15 young women with atherosclerosis of the
distal aorta [27] Several other animal-experimental studies
correlated older oral contraceptive formulations contammg
high doses of potent synthetic estrogens and progestagens to
mcreased nsk of arterial thrombosis [28] One recently pub-
lished study exammed the effect of current low-dose oral con-
traceptives on arterial thrombosis and concluded that current
oral contraceptive regimens did not increase the susceptibility
of the artery wall to develop an occlusive thrombus In fact,
there was a reduction in the incidence of thrombosis in the oral
contraceptive animals compared with untreated control subjects
[29] Our results do not support this expenmental observation
Aspects of the design of our study
Our study was a nationwide multicenter population-based case-
control study, and the first study to evaluate the relationship
between the use of oial contraceptives and the risk of PAD in
young women A unique feature of this study was the high
Proportion of oral contraceptive users m the patient and control
group, 51% and 38%, respectively Taken together with the
large number of patients and controls, this mostly resulted in
precise estimates
In this study, data were collected by a self-admimstered
questionnaire and we provided color photographs of all mar-
keted pills However, we are confident that the presence of
severe illnesses, or current pill use, will have been reported
correctly m the majonty of cases, because several studies which
assessed the vahdity of seif reported pill use [30], concluded
that acceptably valid oral contraceptive histones were obtamed
with a self-admimstered questionnaire A more recent survey on
the validation of cardiovascular nsk factors also revealed a high
agreement between questionnaire Information and medical
records [31]
We only compared current users of oral contraceptives with
non-users (never users and past users combmed), because
previous studies reported that the adverse effects of combmed
oral contraceptives, platelet hyperactivity, blood pressure ele-
vation, decreased glucose tolerance, and unfavorable hpid
profile, disappeared when oral contraceptives are discontmued
[2,32] However, all these studies mcluded patients with myo-
cardial infarction or patients with cerebral vascular disease,
which are vascular diseases with a thrombotic component In
our study, we mcluded patients with PAD, which is of a more
chronic (atheromatous) rather than an acute nature (thrombo-
tic) However, we do not thmk that this division is absolute, nor
that there are no similanties, with angma pectons and claudi-
catio intermittens äs an obvious example We believe that a view
of all these arterial disease äs mamfestations of a similar disease
etiology, consistmg of an interplay between atherosclerotic and
thrombotic phenomena, is not unusual For this reason, exam-
ining pill use m this context äs it has been done in many studies
on other vascular diseases, with an emphasis on current use, is
not out of the ordmary Our study should be seen äs a first step,
demonstrating an association between oral contraceptive use
and the occurrence of PAD
Subsequent studies will be necessary to extend our findmgs
of this association mto details, relatmg to duration of use, and
look mto the mechamsm by which oral contraceptives mduce
PAD, for which assessment of duration of use may prove useful
Conclusion
The results of this study showed that current oral contraceptive
use is associated with a threefold mcreased risk of PAD There
was no difference between oral contraceptives contammg sec-
ond and those contammg third generation progestagens
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